Sacituzumab Govitecan vs Sacituzumab Tirumotecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT05089734 · Phase 3 · active, not recruiting

This was a randomized, open-label Phase 3 trial of 603 patients comparing sacituzumab govitecan to docetaxel, using overall survival (a hard clinical endpoint) as the primary measure. Although the drug showed a numerical survival advantage (11.1 vs 9.8 months), the difference did not reach statistical significance (p=0.0534), so the trial's primary comparison was not formally met despite a reasonably strong and adequately powered design.

Next expected readout: January 2027 · NCT05609968 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 24.4 months): EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant (missed)

Result source: NCT05089734

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT05870319 · Phase 3 · active, not recruiting

This is a randomized, adequately sized (n=376) trial with an active comparator (standard chemotherapy) and a hard clinical endpoint (progression-free survival), and the result was strongly positive favoring the drug. However, the study was conducted open-label with no blinding, which limits confidence in a design that would otherwise support a top-tier grade despite the clear and statistically robust result.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT06448312 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months): OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 (met)

Result source: NCT05870319

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSacituzumab GovitecanSacituzumab Tirumotecan
PFS, median—Trial running · NCT05609968—Trial running · NCT05870319
OS, median—Trial running · NCT05609968—Trial running · NCT05870319
ORR—Trial running · NCT05609968—Trial running · NCT05870319
Duration of response, median—Trial running · NCT05609968—Trial running · NCT05870319

PFS, median

Sacituzumab Govitecan
—Trial running · NCT05609968
Sacituzumab Tirumotecan
—Trial running · NCT05870319

OS, median

Sacituzumab Govitecan
—Trial running · NCT05609968
Sacituzumab Tirumotecan
—Trial running · NCT05870319

ORR

Sacituzumab Govitecan
—Trial running · NCT05609968
Sacituzumab Tirumotecan
—Trial running · NCT05870319

Duration of response, median

Sacituzumab Govitecan
—Trial running · NCT05609968
Sacituzumab Tirumotecan
—Trial running · NCT05870319
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Govitecan
EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant NCT05089734 · Phase 3 · design grade: moderate · publication or press release
Sacituzumab Tirumotecan
OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 NCT05870319 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Sacituzumab Govitecan: 1 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSacituzumab Govitecan
Dropout rate
4.8%10 mg/kga
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—10 mg/kga
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Serious AEs
—10 mg/kga
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Approved in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT03901339 · Phase 3 · completed

The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)

Result source: NCT03901339

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06081959 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSacituzumab GovitecanSacituzumab Tirumotecan
PFS, median5.5 vs 4vs Treatment of Physician's Choicen 272NCT03901339
1 other result
—Trial running · NCT06312176
OS, median14.5 vs 11.2vs Treatment of Physician's Choicen 272NCT03901339—Trial running · NCT06312176
ORR—Trial running · NCT05840211—Trial running · NCT06312176
Clinical benefit rate—Trial running · NCT05840211—Trial running · NCT06312176

PFS, median

Sacituzumab Govitecan
5.5 vs 4vs Treatment of Physician's Choicen 272NCT03901339
1 other result
Sacituzumab Tirumotecan
—Trial running · NCT06312176

OS, median

Sacituzumab Govitecan
14.5 vs 11.2vs Treatment of Physician's Choicen 272NCT03901339
Sacituzumab Tirumotecan
—Trial running · NCT06312176

ORR

Sacituzumab Govitecan
—Trial running · NCT05840211
Sacituzumab Tirumotecan
—Trial running · NCT06312176

Clinical benefit rate

Sacituzumab Govitecan
—Trial running · NCT05840211
Sacituzumab Tirumotecan
—Trial running · NCT06312176
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Sacituzumab Tirumotecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Sacituzumab Govitecan: 2 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSacituzumab Govitecan
Dropout rate
n/a: no completion milestone
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
—
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
27.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
neutropenia 68.7%
diarrhoea 60.8%
nausea 58.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sacituzumab Govitecan

PFS 5.5 vs 4 Treatment of Physician's Choice months
time to event · months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
4.3 vs 3.1 Treatment of Physician's Choice months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival 14.5 vs 11.2 Treatment of Physician's Choice months
time to event · months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 21.3% (n=272) vs 14% (n=271) Treatment of Physician's Choice
responder rate · % of participants
ORR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 8.1 vs 5.6 Treatment of Physician's Choice months
time to event · months
DOR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 33.8% (n=272) vs 22.1% (n=271) Treatment of Physician's Choice
responder rate · % of participants
CBR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Breast Cancer

Shared mechanism: TROP2 · full Breast Cancer pipeline

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Approved in Breast Cancerantibody-drug conjugate
Partial signal

NCT03901339 · Phase 3 · completed

The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)

Result source: NCT03901339

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in Breast Cancerantibody-drug conjugate
Partial signal

NCT05347134 · Phase 3 · active, not recruiting

This was a randomized, adequately sized (n=254) phase 3 trial with an active chemotherapy comparator and a hard clinical endpoint (progression-free survival, reviewed independently), and it clearly succeeded, showing a large PFS benefit for sac-TMT over chemotherapy. However, the trial was open-label with no blinding of patients or investigators, which limits confidence in any endpoints subject to subjective influence, so despite the strong result this design element keeps the grade at moderate rather than the highest tier.

Next expected readout: December 2026 · NCT06081959 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (up to 24 months): OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 (met)

Result source: NCT05347134

Results for Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Tirumotecan
OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 NCT05347134 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sacituzumab Govitecan

PFS 5.5 vs 4 Treatment of Physician's Choice months
time to event · months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
4.3 vs 3.1 Treatment of Physician's Choice months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
5.6 vs 1.7 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
4.8 vs 1.7 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Overall Survival 14.5 vs 11.2 Treatment of Physician's Choice months
time to event · months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
12.1 vs 6.7 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
11.8 vs 6.9 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
ORR 21.3% (n=272) vs 14% (n=271) Treatment of Physician's Choice
responder rate · % of participants
ORR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 8.1 vs 5.6 Treatment of Physician's Choice months
time to event · months
DOR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 33.8% (n=272) vs 22.1% (n=271) Treatment of Physician's Choice
responder rate · % of participants
CBR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 34.9% (n=235) vs 4.7% (n=233) Treatment of Physician's Choice (TPC)
responder rate · % of participants
ORR by IRC Assessment
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Time to Response 2.14 vs 2.72 Treatment of Physician's Choice (TPC) months
time to event · months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
show 1 more result
2.67 vs 1.86 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Duration of Response 6.3 vs 3.6 Treatment of Physician's Choice (TPC) months
time to event · months
IRC Assessment
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Time to Progression 5.7 vs 1.8 Treatment of Physician's Choice (TPC) months
time to event · months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
show 1 more result
5.8 vs 2.1 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Clinical Benefit 44.7% (n=235) vs 8.6% (n=233) Treatment of Physician's Choice (TPC)
responder rate · % of participants
IRC Assessment
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
EORTC QLQ-C30 Global Health Status -5.8 vs -9.4 Treatment of Physician's Choice (TPC) score
absolute change · score
Global Health Status/QoL: Change From Baseline at EOT
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
EORTC QLQ-C30 Physical Functioning -4.6 vs -13.5 Treatment of Physician's Choice (TPC) score
absolute change · score
Physical Functioning: Change From Baseline at EOT
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3

+ 13 further endpoints in the CSV export.

Available safety results

Sacituzumab Govitecan

Dropout rate
n/a: no completion milestone
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
n/a: no completion milestone
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
4.8%10 mg/kg
NCT01631552 · Phase 1/2
Discontinued due to AEs
—
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
—
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
—10 mg/kg
NCT01631552 · Phase 1/2
Serious AEs
27.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
26.7%
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
—10 mg/kg
NCT01631552 · Phase 1/2
Most frequent reported AEs
neutropenia 68.7%
diarrhoea 60.8%
nausea 58.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 65.1%
nausea 62%
fatigue 51.6%
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sacituzumab Govitecan's landscape · Sacituzumab Tirumotecan's landscape